Hijioka et al. reported that KRAS mutations and loss of Rb1 were associated with better response to PE in pancreatic NEN G3 [74], which was recently supported by data from a French cohort of NEN G3 of different origin, which demonstrated a significantly higher response to PE in the absence of Rb1 staining [75]. Here, KRAS is linked to pancreatic neuroendocrine neoplasm.